Perhaps, the tawa-tawa herb is the first dengue medicine known to man. It has been proven by very few scientific studies and thousands of anecdotal literature. Pharma companies sure not making money from it. The herb can be grown easily and can be found in the wilds.
It is meant to cure, not prevent. Vaccine does that. The DengVaxia® is the first commercially available dengue vaccine introduce in the market.
According to who.int, DengVaxia® or CYD-TDV is the first dengue vaccine to be licensed. It was first licensed in Mexico in December 2015 for use in individuals 9-45 years of age living in endemic areas. CYD-TDV is a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur (CYD-TDV), given as a 3-dose series on a 0/6/12 month schedule.
It has various efficacy levels among age groups. Though licensed, it is still a new drug in stage of clinical trials. Earning cash while getting research data is a dirty trick in my opinion. They should have put more effort into it before making the general public their guinea pigs.
The vaccine already reached the Philippine archipelago. The developer together with Watson’s Personal Care Store planned to conduct immunization service which cost 4,000 pesos per shot. Three shots should be given in a year so it is a whooping 12,000 pesos. Not much if you belong to middle class, consider the dengue danger and cost of hospitalization.
However, Food and Drug Administration (FDA) prevented the act due to the following reasons. Lack of license to conduct immunization service. Drug safety is not assured. Unauthorized advertisement and promotion last April. It leads to misconception that vaccine is over-the-counter where in fact it is a prescription medicine. The agency further stated, they will revoke the product registration if the two companies continue making violations.
Something feels not right here. Certificate of Product Registration never means you can promote, advertise and administer the vaccine. Separate permits are needed for each purpose. And how come the product was approved for registration if its safety is not assured.
According to FiercePharma.com, the vaccine may do more harm than good if used in low-risk area. They stressed, dengue virus works differently than others. Second attack is expected worse than the first. In case a person receives the vaccine. It will be perceived as first infection, without making the body sick. When the same person acquires the virus naturally, the resulting sickness is expected severe. Thus, the vaccine is recommended only in high-risk areas.
Vaccine is a weak version of virus causing disease. Dengue vaccine is the weak version of dengue virus. By getting the shots, you’ll be getting a weaker version of dengue virus that your body’s immune system can easily fight. It helps produce the necessary antibodies to fight the weak and stronger virus.